In Vitro Antifungal Susceptibility of Clinical Species Belonging to Aspergillus Genus and Rhizopus Oryzae Publisher Pubmed



Kachuei R¹ ; Khodavaisy S² ; Rezaie S³ ; Sharifynia S³ Show Affiliations
Source: Journal de Mycologie Medicale Published:2016

Abstract

Objective: Among filamentous fungal pathogens, Aspergillus spp. and zygomycetes account for highest rates of morbidity and mortality among immunocompromised patients. Recently developed antifungal drugs offer the potential to improve management and therapeutic outcomes of fungal infections. The aim of this study was to analyse the in vitro activities of voriconazole, itraconazole, amphotericin B and caspofungin against clinical isolates of Aspergillus spp. and Rhizopus oryzae. Material and methods: The in vitro antifungal susceptibility of 54 isolates belonging to different clinical isolates of Aspergillus spp. and R. oryzae was tested for four antifungal agents using a microdilution reference method (CLSI, M38-A2). All isolates were identified by typical colony and microscopic characteristics, and also characterized by molecular methods. Results: Caspofungin (MEC range: 0.008-0.25 and MEC50: 0.0023 μg/mL) was the most active drug in vitro against Aspergillus spp., followed by voriconazole (MIC range: 0.031-8 and MIC50: 0.5 μg/mL), itraconazole (MIC range: 0.031-16 and MIC50: 0.25 μg/mL), and amphotericin B (MIC range: 0.125-4 and MIC50: 0.5 μg/mL), in order of decreasing activity. The caspofungin, voriconazole, and itraconazole demonstrated poor in vitro activity against R. oryzae isolates evaluated, followed by amphotericin B. © 2016 Elsevier Masson SAS.